Effect of treatment by nasal continuous positive airway pressure on serum high mobility group box-1 protein in obstructive sleep apnea.
BACKGROUND
Serum levels of high mobility group box-1 protein (HMGB1) are increased in a variety of inflammatory disorders. Obstructive sleep apnea syndrome (OSAS) is associated with inflammation secondary to chronic intermittent hypoxia, but HMGB1 levels in treated and untreated OSAS have not been evaluated.


METHODS
Twenty healthy subjects and 30 subjects with moderately severe or severe OSAS who desired nasal continuous positive airway pressure (CPAP) treatment were enrolled. Serum levels of HMGB1 and nitric oxide derivative (NO(x)) from peripheral blood samples were measured, and all subjects underwent a sleep study. These studies were repeated 2 months after nasal CPAP treatment in the patients with OSAS.


RESULTS
In OSAS before nasal CPAP treatment, the serum level of HMGB1 was higher but that of NO(x) was lower than those levels of normal subjects. The HMGB1 levels correlated negatively with NO(x) levels in subjects with OSAS. After nasal CPAP treatment, the HMGB1 and NO(x) returned to normal levels.


CONCLUSIONS
Elevated HMGB1 levels and reduced NO(x) levels in patients with OSAS normalized after nasal CPAP treatment.
Wu
Kun-Ming
KM
Chest Division, Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan.
Lin
Ching-Chi
CC
Chiu
Chung-Hsin
CH
Liaw
Shwu-Fang
SF
D015415:Biomarkers / Q000097:blood; D045422:Continuous Positive Airway Pressure / Q000379:methods*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005500:Follow-Up Studies; D024243:HMGB1 Protein / Q000097:blood*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009569:Nitric Oxide / Q000097:blood; D020181:Sleep Apnea, Obstructive / Q000097:blood / Q000628:therapy*; D016896:Treatment Outcome
D015415:Biomarkers; D024243:HMGB1 Protein; D009569:Nitric Oxide